TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12676601
Drug: Combustion particles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combustion particles (1.0 mg/m3)
Study: 3008313
Drug: i.v. applicable
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. applicable CMV-hyperimmunoglobulin administered prior to transplant
Study: 25239590
Drug: Prucalopride (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride (0.04 mg/kg oral solution for children ≤ 50 kg; 2 mg tablet for children > 50 kg) once daily for 8 weeks
Study: 11669594
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: continuous circadian intra-arterial infusion of 1400 mg/m² 5-FU plus 60 mg/m² i.v. leucovorin and 80 µg/m² GM-CSF (day 1+2) combined with chemoembolization with 25 mg/m² melphalan plus Lipiodol and Gelfoam (day 3)
Study: 9209730
Drug: Clozapine serum
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine serum level 50-150 ng/mL
Study: 9209730
Drug: Clozapine serum
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine serum level 200-300 ng/mL
Study: 9209730
Drug: Clozapine serum
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine serum level 350-450 ng/mL
Study: 9209730
Drug: Clozapine treatment
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine treatment (general)
Study: 2142921
Drug: Intranasal buserelin
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal buserelin (500 micrograms thrice daily for 10 days, then intranasal)
Study: 2142921
Drug: Subcutaneous goserelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous goserelin
Study: 25078981
Drug: Retinaldehyde-based cream
Normalized name: retinaldehyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinaldehyde-based cream (RA-cream) applied once daily for 3 months
Study: 25078981
Drug: Control cream
Normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control cream applied once daily for 3 months
Study: 16620353
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ipratropium bromide and salbutamol sulphate
Study: 2433406
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with cisplatin, bleomycin, and methotrexate with oral calcium leucovorin (PBM)
Study: 2433406
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with PBM
Study: 31945197
Drug: URO-902 5000
Normalized name: ADHESIVE,URO-BOND 5000 LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: URO-902 5000 µg
Study: 31945197
Drug: URO-902 16,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: URO-902 16,000 µg
Study: 20610442
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with infliximab
Study: 20610442
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with methotrexate
Study: 16390893
Drug: Vardenafil 10
Normalized name: vardenafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil 10 mg/day (with titration options to 5 mg/day or 20 mg/day)
Study: 11287025
Drug: Lisuride maleate
Normalized name: lisuride maleate
DrugBank: Lisuride (DB00589)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisuride maleate (0.2 mg daily for 2 months)
Study: 11287025
Drug: Placebo (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.2 mg daily for 2 months)
Study: 31145549
Drug: Serum vitamin
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum vitamin D levels <10 ng/mL
Study: 31145549
Drug: Serum vitamin
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum vitamin D levels ≥10 ng/mL
Study: 31145549
Drug: Serum vitamin
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum vitamin D level ≥10 ng/mL
Study: 28081633
Drug: Activity-oriented treatment
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity-oriented treatment (10 days, 30 minutes each day)
Study: 24273976
Drug: Tianxinfu adsorbable
Normalized name: diphtheria toxoid adsorbed
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianxinfu adsorbable biomembrane + Danhong Injection (Group D)
Study: 11226005
Drug: Rituximab at
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab at escalated doses (initial dose of 375 mg/m2, maximum dose of 2,250 mg/m2)
Study: 6374055
Drug: Adjuvant doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant doxorubicin 90 mg/m2 every three weeks (20 patients)
Study: 26370923
Drug: Spironolactone 100
Normalized name: spironolactone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 100 mg/d
Study: 26370923
Drug: Spironolactone 100
Normalized name: spironolactone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 100 mg/d plus Metformin 2000 mg/d
Study: 24423186
Drug: Intravenous ferrous
Normalized name: Ferrous Fumarate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferrous sucrose (200 mg/24 hours for two consecutive days)
Study: 9185039
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with subconjunctival retention of 0.5 mL pure C3F8 gas (Group B)
Study: 1981075
Drug: Atenolol (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50-100 mg given once a day for 4 days)
Study: 29032921
Drug: Optimel eye
Normalized name: glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimel eye drops (Manuka honey) used twice a day for two weeks
Study: 20978545
Drug: Surgery-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery-based treatment
Study: 17079058
Drug: Aluminum adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum adjuvanted eleven‐valent pneumococcal conjugate vaccine (11PncTD)
Study: 10533327
Drug: Rectal Misoprostol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal Misoprostol® 200 ug
Study: 10533327
Drug: Rectal Misoprostol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal Misoprostol® 400 ug
Study: 10533327
Drug: Combined intramuscular
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intramuscular oxytocin and ergometrine (O‐E)
Study: 10533327
Drug: Rectal Misoprostol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal Misoprostol® (200 ug and 400 ug)
Study: 10533327
Drug: Rectal Misoprostol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal Misoprostol®
Study: 161652
Drug: Lillehei-Kaster (L-K)
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lillehei-Kaster (L-K) valves
Study: 2547470
Drug: Ramipril 10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 10 mg daily
Study: 31119689
Drug: Amlodipine/valsartan 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan 10 mg/160 mg + rosuvastatin 20 mg
Study: 23422495
Drug: Everolimus 3-8
Normalized name: everolimus 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 3-8 ng/mL
Study: 23422495
Drug: Everolimus 6-12
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus 6-12 ng/mL
Study: 23422495
Drug: Mycophenolic acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mycophenolic acid (MPA) 1.44 g per day
Study: 17182126
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G‐CSF) treatment started within 24 hours after PCI.
Study: 17182126
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no G‐CSF treatment).
Study: 14996877
Drug: Deflazacort (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflazacort (treatment group)
Study: 28454836
Drug: Losartan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (150 mg once daily)
Study: 16838234
Drug: Piperacillin-tazobactam (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam (4.5 g every 6 h)
Study: 16838234
Drug: Cefepime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (2 g every 8 h)
Study: 20139231
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg/d)
Study: 18724188
Drug: Eban HIV/STD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eban HIV/STD Risk Reduction Intervention (treatment)
Study: 12434307
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate 0.5% gel forming solution (TXE)
Study: 2022266
Drug: Vaginal bromocriptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal bromocriptine (2.5 mg)
Study: 2022266
Drug: Oral bromocriptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bromocriptine (2.5 mg)
Study: 28577671
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment in patients with DM
Study: 28577671
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment among DM patients
Study: 7912946
Drug: urapidil 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: urapidil 0.4 mg kg‐1 i.v.
Study: 28121670
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor containing
Study: 24288494
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (20 sessions, every other day, 20 minutes each session)
Study: 25226827
Drug: Glutamine supplementation
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine supplementation (0.5 g/KgBW/day)
Study: 25226827
Drug: Isonitrogenous protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isonitrogenous protein supplement (0.5 g/KgBW/day)
Study: 21872935
Drug: Ranibizumab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.5 mg)
Study: 20172072
Drug: Bevacizumab (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (1.25 mg)
Study: 20825712
Drug: peginterferon α‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon α‐2a 180 microg injection once a week in combination with ribavirin 800‐1200 mg/d for 48 weeks
Study: 20825712
Drug: peginterferon α‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon α‐2a 180 microg injection once a week in combination with ribavirin 800‐1200 mg/d for 72 weeks
Study: 16398772
Drug: Intrauterine lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine lignocaine (5 mL of 2% lignocaine)
Study: 11019370
Drug: 5'-DFUR (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'-DFUR (600 mg/day for 2 years)
Study: 1484176
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRIs), specifically sertraline
Study: 29615088
Drug: Ultrasound-guided needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided needle release of the TCL plus corticosteroid injection (group A)
Study: 20945036
Drug: Isoflavone extract
Normalized name: flaxseed extract 250 MG / soy isoflavones 250 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone extract (80 mg daily for 4 months)
Study: 7503080
Drug: Postcontrol study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postcontrol study after discontinuation of treatment
Study: 31549310
Drug: Cooperative parent-mediated
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooperative parent-mediated therapy (CPMT)
Study: 31172338
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine with buccal midazolam
Study: 20674417
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg ondansetron
Study: 25812804
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml normal saline (Control)
Study: 17028992
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioral stress management expressive supportive therapy (CBSM+) intervention plus a healthier lifestyles (HL) component
Study: 10632913
Drug: Tropisetron 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 0.2 mg.kg‐1 up to 5 mg
Study: 9162432
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose insulin (physiological concentration)
Study: 9162432
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose insulin (physiological concentration)
Study: 6337767
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no insulin)
Study: 26694545
Drug: GLP‐1 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP‐1 receptor antagonist exendin‐(9‐39)
Study: 22456303
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution of lesogaberan (100 mg)
Study: 22456303
Drug: Modified release
Normalized name: MODIFIED RELEASE CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified release (MR) capsules of lesogaberan (50% dissolution over 4 h)
Study: 22456303
Drug: Modified release
Normalized name: MODIFIED RELEASE CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified release (MR) capsules of lesogaberan (100% dissolution over 4 h)
Study: 16009907
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon beta 1a
Study: 11850287
Drug: GW 420867X
Normalized name: GW 468816
DrugBank: GW 468816 (DB05417)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW 420867X 200 mg
Study: 10420495
Drug: Fluoxetine (FLX)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (FLX) 40 mg or 60 mg per day
Study: 10420495
Drug: Fluoxetine (FLX)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (FLX) 20 mg per day
Study: 7674813
Drug: Besipirdine hydrochloride
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Besipirdine hydrochloride (10, 20, 30, 40 mg bid for 2 days each, followed by 50 and 60 mg bid for 5 days each)
Study: 26809247
Drug: Temporary fracture
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporary fracture fixation with external fixation and defined secondary definitive treatment (DCO)
Study: 23461895
Drug: BMS-936557 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-936557 (10 mg/kg) intravenously every other week
Study: 22100823
Drug: Fentanyl 10
Normalized name: FENTANYL 100MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 10 μg
Study: 22100823
Drug: Fentanyl 25
Normalized name: FENTANYL 25MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 25 μg
Study: 22100823
Drug: Fentanyl 0
Normalized name: fentanyl 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0 μg
Study: 21568143
Drug: Cyanoacrylate injection
Normalized name: ethyl cyanoacrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyanoacrylate injection
Study: 19298364
Drug: Parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg i.v. (Group Ia, n=54)
Study: 19298364
Drug: Parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg i.v. (Group Ia and IIa)
Study: 23446897
Drug: Choline intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline intake of 930 mg/d
Study: 28844293
Drug: Maropitant (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maropitant (1 mg kg−1, n = 12)
Study: 28844293
Drug: Saline (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.1 mL kg−1, n = 12)
Study: 25877989
Drug: MPH-MLR (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPH-MLR (various doses)
Study: 23522432
Drug: Low-carbohydrate (LC)
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-carbohydrate (LC) diet (initial carbohydrate intake 20 g/d, with a 10 g increase weekly)
Study: 23522432
Drug: Energy-restricted (ER)
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy-restricted (ER) diet (carbohydrate intake 156-205 g/d, ER to 5021 or 6276 kJ/d, 35% average energy reduction)
Study: 11300610
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of GFR changes between BG<10 mmol/L and BG>15 mmol/L
Study: 9043962
Drug: Fluoxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (60 mg once a day)
Study: 31302249
Drug: GGA 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: GGA 400 mg/day
Study: 23194023
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones 60 mg and Lactobacillus sporogenes 1 billion spores
Study: 17008704
Drug: Preoperative chemoradiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiotherapy (fluorouracil 350 mg/m2/d during 5 days with leucovorin, 45 Gy in 25 fractions over 5 weeks)
Study: 1700203
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg of enoximone orally
Study: 7771914
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride (0.5 mg/kg)
Study: 25659029
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (eight doses, two clustered doses over 3 weeks)
Study: 15083312
Drug: L. helveticus
Normalized name: L. helveticus,rhamnosus/B. longum/zinc yeast/selenium yeast 2 billion cell-2 mg-12.5 mcg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. helveticus fermented milk
Study: 15083312
Drug: L. helveticus
Normalized name: L. helveticus,rhamnosus/B. longum/zinc yeast/selenium yeast 2 billion cell-2 mg-12.5 mcg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. helveticus derived peptides
Study: 9718254
Drug: phenytoin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: phenytoin (300 mg p.o.)
Study: 7862843
Drug: Diazepam (0.18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.18 mg/kg)
Study: 3434168
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine infusions
Study: 3434168
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (single dose of intercostal bupivacaine)
Study: 28591071
Drug: Intra-articular (IA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular (IA) steroid injection (0.5 mL of 0.5% bupivacaine mixed with 10 mg dexamethasone)
Study: 27619779
Drug: 105 mg
Normalized name: menthol 105 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 105 mg oxybutynin patch
Study: 27619779
Drug: 73.5 mg
Normalized name: silymarin 73.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 73.5 mg oxybutynin patch
Study: 19937427
Drug: 360 microg
Normalized name: Interferon alfa-2a (as peginterferon alfa-2a) 360 microgram/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 microg MK-7 in the form of Natto capsules
Study: 12765846
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules containing olive oil
Study: 8730004
Drug: Low-dose theophylline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose theophylline
Study: 9470081
Drug: Selective digestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective digestive decontamination (SDD) with oral non-absorbable antibiotics (polymyxin E, tobramycin and amphotericin B)
Study: 9470081
Drug: No administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: No administration (Control group)
Study: 3673207
Drug: Purified chick
Normalized name: rabies vaccine, purified chick embryo cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified chick embryo cell culture rabies vaccine (PCECV)
Study: 3673207
Drug: Human diploid
Normalized name: rabies vaccine, human diploid cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human diploid cell strain rabies vaccine (HDCSV)
Study: 28920356
Drug: Choudongning (CDN)
Normalized name: rsATP7A cDNA
DrugBank: rsATP7A cDNA (DB17854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choudongning (CDN) capsule
Study: 28920356
Drug: Tiapridal tablets
Normalized name: tiapride
DrugBank: Tiapride (DB13025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapridal tablets
Study: 17565921
Drug: Intravenous conivaptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous conivaptan 20 mg loading dose (day 1) + 40 mg/d continuous infusion (days 1-4)
Study: 17565921
Drug: Intravenous conivaptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous conivaptan 20 mg loading dose (day 1) + 80 mg/d continuous infusion (days 1-4)
Study: 10456135
Drug: Lacidipine 4
Normalized name: lacidipine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine 4 mg daily (increased to 6 mg if no satisfactory response)
Study: 7524263
Drug: Intravenous, polyethyleneglycol‐treated,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous, polyethyleneglycol‐treated, human immunoglobulin at 200 mg/kg per day for five consecutive days (group A)
Study: 7524263
Drug: Freeze‐dried, sulfonated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze‐dried, sulfonated human immunoglobulin at 200 mg/kg per day for five consecutive days (group C)